PMID- 29332095
OWN - NLM
STAT- MEDLINE
DCOM- 20180727
LR  - 20181202
IS  - 1423-0224 (Electronic)
IS  - 0302-282X (Linking)
VI  - 75
IP  - 3
DP  - 2017
TI  - Both Serum Brain-Derived Neurotrophic Factor and Interleukin-6 Levels Are Not 
      Associated with Therapeutic Response to Lamotrigine Augmentation Therapy in 
      Treatment-Resistant Depressive Disorder.
PG  - 145-150
LID - 10.1159/000484665 [doi]
AB  - BACKGROUND/AIMS: Serum levels of brain-derived neurotrophic factor (BDNF) and 
      interleukin-6 (IL-6) were prospectively monitored in relation with therapeutic 
      response to lamotrigine augmentation therapy in 46 (15 males and 31 females) 
      inpatients with treatment-resistant depressive disorder during an 8-week 
      treatment with lamotrigine using an open-study design. METHODS: The subjects were 
      46 depressed patients who had already shown insufficient response to at least 3 
      psychotropics including antidepressants, mood stabilizers, and atypical 
      antipsychotics. The diagnoses were major depressive disorder (n = 19), bipolar I 
      disorder (n = 6), and bipolar II disorder (n = 22). The final doses of 
      lamotrigine were 100 mg/day for 26 subjects who were not taking valproate and 75 
      mg/day for 20 subjects taking valproate, respectively. Depressive symptoms were 
      evaluated by the Montgomery-Asberg Depression Rating Scale (MADRS) before and 
      after the 8-week treatment. Blood sampling was performed before the start of 
      lamotrigine treatment and at week 8. Serum BDNF and IL-6 levels were measured 
      using quantitative sandwich enzyme immunoassays. RESULTS: No significant changes 
      in serum BDNF or IL-6 levels during the 8-week lamotrigine treatment were 
      observed in the total of subjects, responders or nonresponders. There was no 
      significant correlation between the changes in serum BDNF or IL-6 levels and the 
      percent improvement in MADRS scores in the overall subjects. CONCLUSION: The 
      present study suggests that the acute effect of lamotrigine augmentation therapy 
      for a major depressive episode is not related to either BDNF or IL-6, at least in 
      patients with treatment-resistant depressive disorder.
CI  - (c) 2018 S. Karger AG, Basel.
FAU - Kagawa, Shoko
AU  - Kagawa S
AD  - Department of Neuropsychiatry, Graduate School of Medicine, University of the 
      Ryukyus, Okinawa, Japan.
FAU - Mihara, Kazuo
AU  - Mihara K
AD  - Department of Neuropsychiatry, Graduate School of Medicine, University of the 
      Ryukyus, Okinawa, Japan.
FAU - Suzuki, Takeshi
AU  - Suzuki T
AD  - Department of Hospital Pharmacy, Graduate School of Medicine, University of the 
      Ryukyus, Okinawa, Japan.
FAU - Nagai, Goyo
AU  - Nagai G
AD  - Department of Neuropsychiatry, Graduate School of Medicine, University of the 
      Ryukyus, Okinawa, Japan.
FAU - Nakamura, Akifumi
AU  - Nakamura A
AD  - Department of Neuropsychiatry, Graduate School of Medicine, University of the 
      Ryukyus, Okinawa, Japan.
FAU - Nemoto, Kenji
AU  - Nemoto K
AD  - Department of Neuropsychiatry, Graduate School of Medicine, University of the 
      Ryukyus, Okinawa, Japan.
FAU - Kondo, Tsuyoshi
AU  - Kondo T
AD  - Department of Neuropsychiatry, Graduate School of Medicine, University of the 
      Ryukyus, Okinawa, Japan.
LA  - eng
PT  - Journal Article
DEP - 20180112
PL  - Switzerland
TA  - Neuropsychobiology
JT  - Neuropsychobiology
JID - 7512895
RN  - 0 (Antidepressive Agents)
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Interleukin-6)
RN  - 0 (Triazines)
RN  - 7171WSG8A2 (BDNF protein, human)
RN  - U3H27498KS (Lamotrigine)
SB  - IM
MH  - Adult
MH  - Antidepressive Agents/*therapeutic use
MH  - Bipolar Disorder/drug therapy
MH  - Brain-Derived Neurotrophic Factor/blood
MH  - Depressive Disorder, Major/drug therapy
MH  - Depressive Disorder, Treatment-Resistant/blood/*drug therapy
MH  - Drug Synergism
MH  - Female
MH  - Humans
MH  - Interleukin-6/*blood
MH  - Lamotrigine
MH  - Male
MH  - Middle Aged
MH  - Psychiatric Status Rating Scales
MH  - Treatment Outcome
MH  - Triazines/*therapeutic use
OTO - NOTNLM
OT  - Augmentation therapy
OT  - Brain-derived neurotrophic factor
OT  - Interleukin-6
OT  - Lamotrigine
OT  - Treatment-resistant depressive disorder
EDAT- 2018/01/15 06:00
MHDA- 2018/07/28 06:00
CRDT- 2018/01/15 06:00
PHST- 2017/06/02 00:00 [received]
PHST- 2017/10/24 00:00 [accepted]
PHST- 2018/01/15 06:00 [pubmed]
PHST- 2018/07/28 06:00 [medline]
PHST- 2018/01/15 06:00 [entrez]
AID - 000484665 [pii]
AID - 10.1159/000484665 [doi]
PST - ppublish
SO  - Neuropsychobiology. 2017;75(3):145-150. doi: 10.1159/000484665. Epub 2018 Jan 12.